Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
PROTEINA logo — Our Protein-protein interaction (PPI) analysis platform enab...

PROTEINA

Our Protein-protein interaction (PPI) analysis platform enables quantitative measurements at the single-molecule level

Founded 2015 Korea South Korea South 32 employees Series C Total: $19.00B Biotechnology, Health Care +2

General Information

Company Name PROTEINA
Founded Year 2015
Location Korea South Korea South +1
Employees 32
Industries Biotechnology, Health Care, Life Sciences +1
Funding Stage Series C
Social

Get notified when PROTEINA moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About PROTEINA

PROTEINA is a biotechnology startup based in South Korea, founded in 2015. The company has revolutionized protein analysis with its first-in-class protein-protein interaction (PPI) analysis platform, utilizing proprietary 'single-molecule co-immunoprecipitation' technology for quantitative measurements at the single-molecule level. This innovative platform provides unmatched accuracy and speed in analyzing PPIs, thereby paving the way for new approaches to diagnosing diseases and discovering drug candidates. In its latest funding round in July 2021, PROTEINA secured a significant KRW19.00B Series C investment, attracting a diverse group of investors including LB Investment, Aju IB Investment, Mirae Asset Venture Investment, GNTech VC, Mirae Asset Capital, Posco Capital, Timefolio Asset Management, and K-Run Ventures. This notable investment underscores the confidence of the venture capital community in the potential of PROTEINA's innovative technology and its impact on the biotechnology, healthcare, and pharmaceutical industries. With its extensive expertise in developing assays to measure targeted PPIs and the ability to model drug efficacy based on PPI metrics, PROTEINA is poised to drive significant advances in the understanding and treatment of diseases. Consequently, the company stands as a compelling investment opportunity at the forefront of revolutionizing protein analysis and contributing to advancements in the biotechnology and pharmaceutical sectors. For more information regarding PROTEINA, please visit their website at www.proteina.co.kr.

Taxonomy: protein-protein interaction, PPI analysis, single-molecule co-immunoprecipitation, quantitative measurements, drug efficacy modeling, protein analysis, disease diagnostics, drug discovery, biotech startup, molecular analysis, diagnostic technology, pharmaceutical research, biomedical innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 8
Investor Investor Investor Investor Investor Investor
•••• •••• 		05 Jul 2021
Venture Round •••••• 1
Investor
08 Oct 2018

PROTEINA Alternatives & Competitors

PROTEINA vs
iktos
iktos France

Artificial intelligence for new drug design

Series A
85 employees
AI, Biotechnology
Compare PROTEINA vs iktos
PROTEINA vs
Quantum-Si
Quantum-Si United States

The Protein Sequencing Company™

IPO
186 employees
Biotechnology, Health Care
Compare PROTEINA vs Quantum-Si
PROTEINA vs
Cullgen Inc.
Cullgen Inc. United States

Powering protein degradation for tomorrow's medicines

Acquired
27 employees
Biotechnology, Pharmaceutical
Compare PROTEINA vs Cullgen Inc.

FAQ About PROTEINA

Our Protein-protein interaction (PPI) analysis platform enables quantitative measurements at the single-molecule level
PROTEINA was founded in 2015.
PROTEINA is headquartered in Korea South.
PROTEINA operates in the following industries: Biotechnology, Health Care, Life Sciences, Pharmaceutical.
PROTEINA has approximately 32 employees.
PROTEINA has completed 2 funding rounds, raising a total of $19.00B. The latest funding stage is Series C.
Top alternatives and competitors to PROTEINA include iktos, Quantum-Si, Cullgen Inc., Venquis Therapeutics, Machine Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PROTEINA and iktos are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors PROTEINA and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy